Glenmark Pharmaceuticals Ltd. has moved decisively to fend off alleged attempts by certain local firms in India to infringe on the local patents for its licensed diabetes therapy remogliflozin etabonate, which has had strong run in the country since its launch earlier this year.
Mumbai-based Glenmark had earlier this year moved the Delhi High Court and secured a restraining order against some companies, believed to include Triveni Chemicals and Avanscure Lifesciences Pvt Ltd, among others, that have allegedly been offering for sale the patented sodium
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?